Systematic Identification of Molecular Signatures Dictating Therapeutic Effects of Clinically First-Line Chemotherapy Regimens for Human Gastric Cancer Patients Based on Organoid Model

Abstract

Chemotherapy is the mainstay in the treatment of advanced gastric cancer (GC); yet, GC showed diverse responses to first-line chemotherapy regimens and the underlying molecular basis is still not clear. Here, we established a system that combined organoid-based chemotherapy regimen screening and transcriptome-based evaluation to identify underlying molecular signatures of different responses to chemotherapy. We generated 19 GC patient-derived organoids (PDOs) from surgically resected specimens with corresponding histological characteristics of parent tumors and tested all of the five most commonly used first-line chemotherapy regimens. Based on the treatment responses, PDOs were classified into double-sensitive, single-sensitive, and not-sensitive groups. PDOs that responded well to chemotherapy presented high expression levels of the P53 pathway genes and low expression levels of cell proliferative activity genes. Furthermore, the chemotherapy-based tumor classification of GC was established. The GC tumor classification was verified by multi-omics features from the TCGA dataset and public drug response datasets. In conclusion, this study systematically evaluated clinical chemotherapy regimens for GC and identified chemotherapy response-associated molecular signatures based on human GC organoids, which are beneficial to the precise treatments of GC.

Keywords

chemotherapy / drug screening / gastric cancer / molecular marker / patient-derived organoid / tumor classification

References

[1] J. A. Ajani, T. A. D'Amico, D. J. Bentrem, et al., “Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology,” Journal of the National Comprehensive Cancer Network 20, no. 2 (2022): 167–192.

[2] R. E. Sexton, M. N. Al Hallak, M. Diab, and A. S. Azmi, “Gastric Cancer: A Comprehensive Review of Current and Future Treatment Strategies,” Cancer and Metastasis Reviews 39, no. 4 (2020): 1179–1203.

[3] Q. Wang, G. Liu, and C. Hu, “Molecular Classification of Gastric Adenocarcinoma,” Gastroenterology Research 12, no. 6 (2019): 275–282.

[4] The Cancer Genome Atlas Research Network, "Comprehensive Molecular Characterization of Gastric Adenocarcinoma." Nature 2014; 513(7517): 202–209.

[5] J. Ma, H. Shen, L. Kapesa, and S. Zeng, “Lauren Classification and Individualized Chemotherapy in Gastric Cancer,” Oncology Letters 11, no. 5 (2016): 2959–2964.

[6] D. Marrelli, K. Polom, V. Pascale, et al., “Strong Prognostic Value of Microsatellite Instability in Intestinal Type Non-Cardia Gastric Cancer,” Annals of Surgical Oncology 23, no. 3 (2016): 943–950.

[7] K. G. Yeoh and P. Tan, “Mapping the Genomic Diaspora of Gastric Cancer,” Nature Reviews Cancer 22, no. 2 (2022): 71–84.

[8] W. Jelski and B. Mroczko, “Molecular and Circulating Biomarkers of Gastric Cancer,” IJMS 23, no. 14 (2022): 7588.

[9] J. Drost and H. Clevers, “Organoids in Cancer Research,” Nature Reviews Cancer 18, no. 7 (2018): 407–418.

[10] X. Jiang, L. Oyang, Q. Peng, et al., “Organoids: Opportunities and Challenges of Cancer Therapy,” Frontiers in Cell and Developmental Biology 11 (2023): 1232528.

[11] B. L. LeSavage, R. A. Suhar, N. Broguiere, M. P. Lutolf, and S. C. Heilshorn, “Next-generation Cancer Organoids,” Nature Materials 21, no. 2 (2022): 143–159.

[12] R. J. Porter, G. I. Murray, and M. H. McLean, “Current Concepts in Tumour-Derived Organoids,” British Journal of Cancer 123, no. 8 (2020): 1209–1218.

[13] Y. Saito, T. Muramatsu, and H. Saito, “Establishment and Long-Term Culture of Organoids Derived From Human Biliary Tract Carcinoma,” STAR Protocols 1, no. 1 (2020): 100009.

[14] P. J. Tebon, B. Wang, A. L. Markowitz, et al., “Drug Screening at Single-Organoid Resolution via Bioprinting and Interferometry,” Nature Communications 14, no. 1 (2023): 3168.

[15] C. Calandrini and J. Drost, “Normal and Tumor-Derived Organoids as a Drug Screening Platform for Tumor-Specific Drug Vulnerabilities,” STAR Protocols 3, no. 1 (2022): 101079.

[16] S. Mertens, M. A. Huismans, C. S. Verissimo, et al., “Drug-Repurposing Screen on Patient-Derived Organoids Identifies Therapy-Induced Vulnerability in KRAS-Mutant Colon Cancer,” Cell Reports 42, no. 4 (2023): 112324.

[17] X. Miao, C. Wang, C. Chai, et al., “Establishment of Gastric Cancer Organoid and Its Application in Individualized Therapy,” Oncology Letters 24, no. 6 (2022): 447.

[18] M. Zu, X. Hao, J. Ning, et al., “Patient-Derived Organoid Culture of Gastric Cancer for Disease Modeling and Drug Sensitivity Testing,” Biomedicine & Pharmacotherapy 163 (2023): 114751.

[19] T. Seidlitz and D. E. Stange, “Gastrointestinal Cancer Organoids—Applications in Basic and Translational Cancer Research,” Experimental & Molecular Medicine 53, no. 10 (2021): 1459–1470.

[20] H. H. N. Yan, H. C. Siu, S. Law, et al., “A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening,” Cell Stem Cell 23, no. 6 (2018): 882–897.e11.

[21] Y. Sato, K. Okamoto, Y. Kida, et al., “Overview of Chemotherapy for Gastric Cancer,” JCM 12, no. 4 (2023): 1336.

[22] J. Sastre, J. A. García-Saenz, and E. Díaz-Rubio, “Chemotherapy for Gastric Cancer,” WJG 12, no. 2 (2006): 204.

[23] J. Verweij, M. Clavel, and B. Chevalier, “Paclitaxel (TaxolTM) and Docetaxel (TaxotereTM): Not Simply Two of a Kind,” Annals of Oncology 5, no. 6 (1994): 495–505.

[24] J. D. Lawson, J. K. Sicklick, and P. T. Fanta, “Gastric Cancer,” Current Problems in Cancer 35, no. 3 (2011): 97–127.

[25] H. Wang, M. Guo, H. Wei, and Y. Chen, “Targeting p53 Pathways: Mechanisms, Structures, and Advances in Therapy,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 92.

[26] H. E. Marei, A. Althani, N. Afifi, et al., “p53 signaling in Cancer Progression and Therapy,” Cancer Cell International 21, no. 1 (2021): 703.

[27] S. Dutt, I. Hamza, and T. B. Bartnikas, “Molecular Mechanisms of Iron and Heme Metabolism,” Annual Review of Nutrition 42, no. 1 (2022): 311–335.

[28] K. H. Lin, A. Xie, J. C. Rutter, et al., “Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity,” Cell Metabolism 29, no. 5 (2019): 1217–1231.e7.

[29] V. Fiorito, D. Chiabrando, S. Petrillo, F. Bertino, and E. Tolosano, “The Multifaceted Role of Heme in Cancer,” Frontiers in Oncology 9 (2020): 1540.

[30] S. Kuntz, E. Krieghoff-Henning, J. N. Kather, et al., “Gastrointestinal Cancer Classification and Prognostication From Histology Using Deep Learning: Systematic Review,” European Journal of Cancer 155 (2021): 200–215.

[31] B. Fakhri and K. H. Lim, “Molecular Landscape and Sub-Classification of Gastrointestinal Cancers: A Review of Literature,” Journal of Gastrointestinal Oncology 8, no. 3 (2017): 379–386.

[32] A. Z. Shams and U. Haug, “Strategies for Prevention of Gastrointestinal Cancers in Developing Countries: A Systematic Review,” Journal of Global Health 7, no. 2 (2017): 020405.

[33] Y. Mao, W. Wang, and J. Yang, “Drug Repurposing Screening and Mechanism Analysis Based on Human Colorectal Cancer Organoids,” Protein & Cell 15, no. 4 (2024): 285–304.

[34] M. Hafner, M. Niepel, M. Chung, and P. K. Sorger, “Growth Rate Inhibition Metrics Correct for Confounders in Measuring Sensitivity to Cancer Drugs,” Nature Methods 13, no. 6 (2016): 521–527.

[35] M. Zhang, S. Hu, M. Min, et al., “Dissecting Transcriptional Heterogeneity in Primary Gastric Adenocarcinoma by Single Cell RNA Sequencing,” Gut 70, no. 3 (2021): 464–475.

[36] X. Zhou, J. Yang, Y. Lu, et al., “Relationships of Tumor Differentiation and Immune Infiltration in Gastric Cancers Revealed by Single-Cell RNA-seq Analyses,” Cellular and Molecular Life Sciences 80, no. 2 (2023): 57.

[37] S. Bian, Y. Wang, Y. Zhou, et al., “Integrative Single-Cell Multiomics Analyses Dissect Molecular Signatures of Intratumoral Heterogeneities and Differentiation States of Human Gastric Cancer,” National Science Review 10, no. 6 (2023): nwad094.

[38] S. Li, L. Yuan, Z. Y. Xu, et al., “Integrative Proteomic Characterization of Adenocarcinoma of Esophagogastric Junction,” Nature Communications 14, no. 1 (2023): 778.

[39] Z. L. Liu, H. H. Chen, L. L. Zheng, L. P. Sun, and L. Shi, “Angiogenic Signaling Pathways and Anti-Angiogenic Therapy for Cancer,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 198.

[40] R. Lugano, M. Ramachandran, and A. Dimberg, “Tumor Angiogenesis: Causes, Consequences, Challenges and Opportunities,” Cellular and Molecular Life Sciences 77, no. 9 (2020): 1745–1770.

[41] T. Yamaguchi, S. Fushida, Y. Yamamoto, et al., “Tumor-associated Macrophages of the M2 Phenotype Contribute to Progression in Gastric Cancer With Peritoneal Dissemination,” Gastric Cancer 19, no. 4 (2016): 1052–1065.

[42] B. Ruffell and L. M. Coussens, “Macrophages and Therapeutic Resistance in Cancer,” Cancer Cell 27, no. 4 (2015): 462–472.

[43] J. Barretina, G. Caponigro, N. Stransky, et al., “The Cancer Cell Line Encyclopedia Enables Predictive Modelling of Anticancer Drug Sensitivity,” Nature 483, no. 7391 (2012): 603–607.

[44] F. Iorio, T. A. Knijnenburg, D. J. Vis, et al., “A Landscape of Pharmacogenomic Interactions in Cancer,” Cell 166, no. 3 (2016): 740–754.

[45] W. Yang, J. Soares, P. Greninger, et al., “Genomics of Drug Sensitivity in Cancer (GDSC): A Resource for Therapeutic Biomarker Discovery in Cancer Cells,” Nucleic Acids Research 41, no. D1 (2012): D955–D961.

[46] B. Seashore-Ludlow, M. G. Rees, J. H. Cheah, et al., “Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset,” Cancer Discovery 5, no. 11 (2015): 1210–1223.

[47] M. G. Rees, B. Seashore-Ludlow, J. H. Cheah, et al., “Correlating Chemical Sensitivity and Basal Gene Expression Reveals Mechanism of Action,” Nature Chemical Biology 12, no. 2 (2016): 109–116.

[48] G. Picco, E. D. Chen, L. G. Alonso, et al., “Functional Linkage of Gene Fusions to Cancer Cell Fitness Assessed by Pharmacological and CRISPR-Cas9 Screening,” Nature Communications 10, no. 1 (2019): 2198.

[49] P. Geeleher, N. J. Cox, and R. S. Huang, “Clinical Drug Response Can be Predicted Using Baseline Gene Expression Levels and in Vitro Drug Sensitivity in Cell Lines,” Genome Biology 15, no. 3 (2014): R47.

[50] D. Maeser, R. F. Gruener, and R. S. Huang, “oncoPredict: An R Package for Predicting in Vivo or Cancer Patient Drug Response and Biomarkers From Cell Line Screening Data,” Briefings in Bioinformatics 22, no. 6 (2021): bbab260.

[51] E. C. Smyth, A. Wotherspoon, C. Peckitt, et al., “Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial,” JAMA Oncology 3, no. 9 (2017): 1197.

[52] Z. Li, X. Gao, X. Peng, et al., “Multi-Omics Characterization of Molecular Features of Gastric Cancer Correlated With Response to Neoadjuvant Chemotherapy,” Science Advances 6, no. 9 (2020): eaay4211.

[53] G. Jedlitschky, U. Hoffmann, and H. K. Kroemer, “Structure and Function of the MRP2 (ABCC2) Protein and Its Role in Drug Disposition,” Expert Opinion on Drug Metabolism & Toxicology 2, no. 3 (2006): 351–366.

[54] Y. K. Zhang, Y. J. Wang, P. Gupta, and Z. S. Chen, “Multidrug Resistance Proteins (MRPs) and Cancer Therapy,” Aaps Journal 17, no. 4 (2015): 802–812.

[55] H. Zhang, A. Patel, S. Ma, et al., “In Vitro , in Vivo and Ex Vivo Characterization of Ibrutinib: A Potent Inhibitor of the Efflux Function of the Transporter MRP1,” British Journal of Pharmacology 171, no. 24 (2014): 5845–5857.

[56] A. A. K. El-Sheikh, J. Van Den Heuvel, J. B. Koenderink, and F. G. M. Russel, “Interaction of Nonsteroidal Anti-Inflammatory Drugs With Multidrug Resistance Protein (MRP) 2/ABCC2- and MRP4/ABCC4-Mediated Methotrexate Transport,” Journal of Pharmacology and Experimental Therapeutics 320, no. 1 (2007): 229–235.

[57] S. Feng, G. Qiu, L. Yang, et al., “Omeprazole Improves Chemosensitivity of Gastric Cancer Cells by m6A Demethylase FTO-mediated Activation of mTORC1 and DDIT3 Up-regulation,” Bioscience Reports 41, no. 1 (2021): BSR20200842.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.